Chronic GVHD risk score: a Center for International Blood and Marrow Transplant Research analysis. - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Blood Année : 2011

Chronic GVHD risk score: a Center for International Blood and Marrow Transplant Research analysis.

Mukta Arora
  • Fonction : Auteur
John P Klein
  • Fonction : Auteur
Daniel J Weisdorf
  • Fonction : Auteur
Anna Hassebroek
  • Fonction : Auteur
Mary E D Flowers
  • Fonction : Auteur
Corey S Cutler
  • Fonction : Auteur
Joseph H Antin
  • Fonction : Auteur
Brian J Bolwell
  • Fonction : Auteur
Michael Boyiadzis
  • Fonction : Auteur
Jean-Yves Cahn
  • Fonction : Auteur
Mitchell S Cairo
  • Fonction : Auteur
David A Jacobsohn
  • Fonction : Auteur
Madan Jagasia
  • Fonction : Auteur
Thomas R Klumpp
  • Fonction : Auteur
Stephanie J Lee
  • Fonction : Auteur
Effie W Petersdorf
  • Fonction : Auteur
Stella Santarone
  • Fonction : Auteur
Harry C Schouten
  • Fonction : Auteur
Stephen Spellman
  • Fonction : Auteur
John R Wingard
  • Fonction : Auteur
Mary M Horowitz
  • Fonction : Auteur
Steven Z Pavletic
  • Fonction : Auteur

Résumé

Several risk factors are associated with increased mortality in patients with chronic graft-versus-host disease (cGVHD), but there is considerable variability in the reported factors. Therefore, we evaluated patient, transplantation, and cGVHD characteristics to develop a risk score in 5343 patients with cGVHD. Ten variables were identified as being significant in multivariate analysis of overall survival and nonrelapse mortality (NRM): age, prior acute GVHD, time from transplantation to cGVHD, donor type, disease status at transplantation, GVHD prophylaxis, gender mismatch, serum bilirubin, Karnofsky score, and platelet count. These 10 variables were used to build a cGVHD risk score, and 6 risk groups (RGs) were identified. The 5-year NRM was 5% (1%-9%) in RG1, 20% (19%-23%) in RG2, 33% (29%-37%) in RG3, 43% (40%-46%) in RG4, 63% (53%-74%) in RG5, and 72% (59%-85%) in RG6. The 5-year overall survival was highest at 91% (95% confidence interval [CI]:85%-97%) in RG1, followed by 67% (65%-69%) in RG2, 51% (46%-55%) in RG3, 40% (37%-43%) in RG4, 21% (12%-30%) in RG5, and 4% (0%-9%) in RG6 (all P < .01). This analysis demonstrates the usefulness of data from a large registry to develop risk-score categories for major transplantation outcomes. Validation of this cGVHD risk score is needed in a different population to ensure its broad applicability.

Domaines

Cancer

Dates et versions

hal-00849655 , version 1 (31-07-2013)

Identifiants

Citer

Mukta Arora, John P Klein, Daniel J Weisdorf, Anna Hassebroek, Mary E D Flowers, et al.. Chronic GVHD risk score: a Center for International Blood and Marrow Transplant Research analysis.. Blood, 2011, 117 (24), pp.6714-20. ⟨10.1182/blood-2010-12-323824⟩. ⟨hal-00849655⟩
1334 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More